APA (7th ed.) Citation

M, W., K, I., T, S., R, O., R, S., E, M., . . . S, W. (2025). Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study. Cancers, 17(14), . https://doi.org/10.3390/cancers17142384

Chicago Style (17th ed.) Citation

M, Watanabe, et al. "Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study." Cancers 17, no. 14 (2025). https://doi.org/10.3390/cancers17142384.

MLA (9th ed.) Citation

M, Watanabe, et al. "Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study." Cancers, vol. 17, no. 14, 2025, https://doi.org/10.3390/cancers17142384.